An AI powered data platform to help researchers rapidly identify and evaluate research reagents to investigate and mitigate the effects of COVID-19

人工智能驱动的数据平台，可帮助研究人员快速识别和评估研究试剂，以调查和减轻 COVID-19 的影响

• 批准号: 76378
• 金额: $ 8.43万
• 依托单位: CITEAB LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=76378
• 关键词: AI; powered; data; platform; help

The study of a newly emerged virus like Sars-CoV-2 relies on novel research tools and hundreds of suppliers from across the world are striving to make thousands of such products available to researchers. These tools open new opportunities for experiments, but provide a challenge to researchers; how do they efficiently find the reagents they require for their experiments. Especially when purchasing the wrong reagent can waste weeks of research time. CiteAb will build a dedicated search and discovery platform to help solve this urgent need.We will use our text mining and AI technology to identify the use of Sars-CoV-2/COVID-19 reagents within publications and use it to provide an ongoing stream of data. This cited reagent data will be combined with information from our network of global reagent suppliers to provide a complete overview of available Sars-CoV-2 reagents and how they have been used in published research. We will then build a dedicated Sars-CoV-2/COVID-19 platform to allow researchers to search and evaluate this data.

对像SARS-CoV-2这样新出现的病毒的研究依赖于新的研究工具，来自世界各地的数百家供应商正在努力为研究人员提供数千种此类产品。这些工具为实验提供了新的机会，但也给研究人员带来了挑战：他们如何有效地找到实验所需的试剂。特别是当购买错误的试剂可能会浪费数周的研究时间。CiteAb将建立一个专门的搜索和发现平台，以帮助解决这一迫切需求。我们将使用我们的文本挖掘和人工智能技术来识别出版物中SARS-CoV-2/COVID-19试剂的使用情况，并使用它来提供持续的数据流。这些引用的试剂数据将与我们全球试剂供应商网络的信息相结合，以提供可用的Sars-CoV-2试剂的完整概述以及它们如何用于已发表的研究。然后，我们将建立一个专门的SARS-CoV-2/COVID-19平台，让研究人员搜索和评估这些数据。